Cross-over study of PDLYMT in chronic kidney disease (CKD) patients undergoing hemodialysis therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225039

Enrollment

Registered

2020-01-24

Start date

2020-04-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD patients undergoing hemodialysis therapy

Interventions

investigational material(s) Generic name etc : PDLYMT INN of investigational material : - Therapeutic category code : 341 Agents for artificial kidney dialysis Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients providing written informed consent about participation in this clinical study - Patients aged 20 to 84 years old at the time of informed consent , etc.

Exclusion criteria

Exclusion criteria: - Patients within 3 months of initiating hemodialysis at the time of informed consent - Patients who find it difficult to undergo HD stably during the entire duration of this study - Patients who are pregnant or who have the possibility of pregnancy at the time of informed consent - Patients participating in clinical studies of other drugs, medical devices, etc. at the time of informed consent for this study - Patients who may not be able to be evaluated as described in the protocol due to serious disease - Patients judged by the investigator or sub-investigator to be inadequate for this study , etc.

Design outcomes

Primary

Measure	Time frame
efficacy confirmatory [Efficacy] Reduction ratio	—

Secondary

Measure	Time frame
safety efficacy confirmatory [Efficacy] Correction of serum electrolytes and blood acid-base balance, etc. [Safety] Adverse event, etc.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026